FDA Brief

Warning letters Drugs

FDA warning letter to

MolluscumRx, Inc.

High riskIssued Aug 18, 2023Posted Aug 22, 2023Center for Drug Evaluation and Research | CDER

FDA told MolluscumRx, Inc. of Orlando, Florida that its molluscum lotion and soap are unapproved new drugs sold with unsupported cure claims.

What happened

FDA reviewed the company's website in June 2023, along with its Facebook, Twitter and YouTube pages, which direct consumers to the website to buy the products. FDA found the website offering "MolluscumRx" and "MolluscumRx Soap" with claims that they cure molluscum contagiosum, work within days, and are safe for children as young as 6 months. Because the products are intended to treat disease, FDA treats them as drugs, and no approved application is in effect for them.

What FDA found

  1. The company's website and social media say the products treat molluscum contagiosum, which makes them drugs under the law.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The products are not generally recognized as safe and effective for these uses, so they are "new drugs."

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. The products are sold in interstate commerce without an FDA-approved application, which the law requires for new drugs.

    Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
  4. The products are marketed for children and for a condition that needs a doctor's diagnosis, so people may delay proper care for something more serious.

What FDA wants

FDA asks the company to write within fifteen working days describing the specific steps taken to correct the violations and prevent them from happening again, with supporting documents. If the company believes it is not in violation, it should send its reasoning and supporting information.

Who should pay attention

  • parents shopping online for children's skin treatments
  • retailers and online marketplaces listing natural skin products
  • sellers making disease-treatment claims for plant-based products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk